Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3365398 | 0.82 | HTT (0.56) | CNR1CNR2KMT2AHTTPOLB | |
| SCHEMBL3365429 | 0.75 | CNR1 (0.54) | CNR1CNR2KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL3364663 | 0.73 | CNR1 (0.70) | CNR1CNR2 | |
| SCHEMBL3364995 | 0.72 | CNR1 (0.85) | CNR1CNR2NPC1RAB9APOLB | |
| SCHEMBL3366114 | 0.72 | CNR1 (0.65) | CNR1CNR2KMT2AHTT | |
| SCHEMBL3367684 | 0.72 | CNR1 (0.65) | CNR1CNR2KMT2AHTT | |
| SCHEMBL31518942 | 0.72 | MALT1 (0.55) | KMT2AL3MBTL1MEN1NPC1RAB9A | |
| SCHEMBL3366256 | 0.72 | CNR1 (0.69) | CNR1CNR2 | |
| SCHEMBL3365725 | 0.72 | CNR1 (0.69) | CNR1CNR2 | |
| SCHEMBL3366834 | 0.71 | CNR1 (0.62) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542678-B1 | 1H-1,2,4-TRIAZOLE-3-CARBOXAMIDE DERIVATIVES AS CANNABINOID-CB sb 1 /sb RECEPTOR LIGANDS | SOLVAY PHARM BV (NL) | 2010-02-24 | — | — | EP | disclosed |
| US-7319110-B2 | 1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-01-15 | — | — | US | disclosed |
| EP-1753413-A2 | NOVEL MEDICAL USES OF COMPOUNDS SHOWING CB SB 1/SB -ANTAGONISTIC ACTIVITY AND COMBINATION TREATMENT INVOLVING SAID COMPOUNDS | Solvay Pharmaceuticals GmbH (DE) | 2007-02-21 | — | — | EP | disclosed |
| EP-1542678-A1 | 1H-1,2,4-TRIAZOLE-3-CARBOXAMIDE DERIVATIVES AS CANNABINOID-CB sb 1 /sb RECEPTOR LIGANDS | Solvay Pharmaceuticals B.V. (NL) | 2005-06-22 | — | — | EP | disclosed |
| US-20050124660-A1 | Compounds for treatment of diseases using enzyme inhibitors, cognition activators for nervous system disorders, psychological disorders or obesity in children | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-06-09 | — | — | US | disclosed |
| WO-2005039550-A2 | NOVEL MEDICAL USES OF COMPOUNDS SHOWING CB1-ANTAGONISTIC ACTIVITY AND COMBINATION TREATMENT INVOLVING SAID COMPOUNDS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-05-06 | — | — | WO | disclosed |
| US-20040106614-A1 | 1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2004-06-03 | — | — | US | disclosed |
| WO-2004026301-A1 | 1H-1,2,4-TRIAZOLE-3-CARBOXAMIDE DERIVATIVES AS CANNABINOID-CB1 RECEPTOR LIGANDS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106614-A1 | 1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity | CNR1, CNR2, GPR3 | CNR1 1/4885KDM4E 2773/4885CNR2 2/4885 |
| US-20050124660-A1 | Compounds for treatment of diseases using enzyme inhibitors, cognition activators for nervous system disorders, psychological disorders or obesity in children | PNLIP, DLAT, LPCAT3 | CNR1 46/4885KDM4E 2948/4885CNR2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.